Benzinga
Benzinga
Benzinga
mardi, septembre 15

Scinai Immunotherapeutics Ltd

SCNINASDAQ
Trade with Public
Trade with Public
$1.54
-0.90-36.89%
À la clôture: Sep 15, 5:00 PM EST
$1.42
-0.12-7.84%
Après les heures: 6:40 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsDonnées financièresSentimentComparerRapport sur les stocks

Scinai Immunotherapeutics Financials

Scinai Immunotherapeutics (SCNI) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Scinai Immunotherapeutics H1 Net Income $1.6M Vs Loss $4.1M Prior Year; Revenues $949K Up From $773K YoY; Continues To Pursue ~$5M In CDMO Revenues For 2026

Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDTJERUSALEM, Aug. 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical
Benzinga Newsdesk

PRO
Scinai Immunotherapeutics FY EPS $(3.56), Sales $1.311M Up From $658.000K YoY

Scinai Immunotherapeutics (NASDAQ:SCNI) reported quarterly losses of $(3.56) per share. The company reported $1.311 million in sales this quarter. This is a 99.24 percent increase over sales of $658.000 thousand the
Benzinga Newsdesk

PRO
Scinai Revenues For Six Months Ended Jun. 30 $773K vs $284K YoY

Benzinga Newsdesk

PRO
Scinai Immunotherapeutics 2024 Revenue $658K

Benzinga Newsdesk

PRO
Scinai Immunotherapeutics Q3 EPS $0.0021 Up From $(0.002) YoY, Sales $168K

Benzinga Newsdesk

Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July

Avi Kapoor

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved